Opus Genetics has completed enrollment for its pivotal Phase 3 clinical trial of OPGx-LCA5, an investigational gene therapy for a rare inherited retinal disease. This milestone, achieved with FDA alignment, positions the company for potential BLA submission based on 6-month efficacy data, with topline results expected by late 2027.
Opus Genetics announced the completion of patient enrollment in its registrational Phase 3 clinical trial for OPGx-LCA5, a gene therapy for LCA5-associated inherited retinal disease. This is a significant de-risking event for the company, as it moves the therapy closer to potential market approval. The trial design was developed in collaboration with the FDA through the Rare Disease Evidence Principles (RDEP) program, suggesting a higher likelihood of regulatory success. The company expects to initiate dosing in Q4 2026 and release topline 6-month efficacy data by the end of 2027, which could trigger a Biologics License Application (BLA) submission. This news is a strong positive for IRD, as successful development and approval of OPGx-LCA5, especially with the potential for a Rare Pediatric Disease Priority Review Voucher, could significantly boost its valuation and market position in the ultra-rare disease space.